促性腺激素释放激素激动剂预处理对子宫腺肌症女性新鲜与冻融胚胎移植结局的影响:一项回顾性队列研究及文献综述
该回顾性队列研究纳入369名子宫腺肌症女性的413个胚胎移植周期,分析GnRHa预处理与新鲜及冻融胚胎移植临床结局的关联。结果显示GnRHa预处理组活产率在新鲜周期(41.27% vs 24.32%,p=0.034)和冻融周期(40.36% vs 20.75%,p=0.008)均高于非预处理组;校正混杂因素后,新鲜周期OR为2.65(95%CI 1.19-5.92),冻融周期OR为2.43(95%CI 1.10-5.40)。Meta分析合并六项研究调整OR后,新鲜周期OR为1.71(95%CI 1.30-2.26),冻融周期OR为2.61(95%CI 1.52-4.49)。结论认为GnRHa预处理可能有利于子宫腺肌症患者新鲜及冻融胚胎移植后的活产率。
要点
- 子宫腺肌症患者GnRHa预处理后新鲜胚胎移植活产率41.27% vs 24.32%(p=0.034)。
- 冻融胚胎移植活产率GnRHa预处理组40.36% vs 20.75%(p=0.008)。
- 作者认为GnRHa预处理可能有利于新鲜及冻融胚胎移植后的活产率。
核心结论
- 在子宫腺肌症女性中,GnRHa预处理可能有利于新鲜胚胎移植和冻融胚胎移植后的活产率。
研究设计与样本
- 回顾性队列研究及文献综述,纳入北京大学第一医院369名子宫腺肌症女性的413个胚胎移植或冻融胚胎移植周期。
- 采用逻辑回归分析和Meta分析评估GnRHa预处理与新鲜及冻融胚胎移植临床结局的关联。
主要发现
- 新鲜胚胎移植中,GnRHa预处理组活产率41.27% vs 非预处理组24.32%(p=0.034)。
- 冻融胚胎移植中,GnRHa预处理组活产率40.36% vs 非预处理组20.75%(p=0.008)。
- 校正混杂因素后,新鲜胚胎移植中GnRHa预处理组活产调整OR为2.65(95%CI 1.19-5.92,p=0.017)。
- 校正混杂因素后,冻融胚胎移植中GnRHa预处理组活产调整OR为2.43(95%CI 1.10-5.40,p=0.029)。
- Meta分析纳入八项符合标准的研究,其中六项报告调整OR;合并这六项调整OR与本研究发现GnRHa预处理组活产率高于非预处理组(新鲜胚胎移植:OR 1.71,95%CI 1.30-2.26;冻融胚胎移植:OR 2.61,95%CI 1.52-4.49)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the effect of gonadotropin-releasing hormone agonist (GnRHa) pre-treatment on the clinical outcomes of fresh and frozen embryo transfers (ETs and FETs, respectively) in infertile patients with adenomyosis. DESIGN: Retrospective cohort study with literature review. SETTING: Peking University First Hospital. POPULATION: We analysed 413 cycles of 369 women with adenomyosis who underwent ETs or FETs. METHODS: We performed logistic regression analysis and meta-analysis to assess the association of GnRHa pre-treatment with the clinical outcomes of ETs and FETs. MAIN OUTCOME MEASURES: The live birth rate (LBR) was compared between patients with and without GnRHa pre-treatment. RESULTS: The LBR was higher in the GnRHa pre-treatment group than in the non-GnRHa pre-treatment group in ETs (41.27% vs. 24.32%, p = 0.034) and FETs (40.36% vs. 20.75%, p = 0.008). The odds of achieving a live birth of women with GnRHa pre-treatment were 2.65 times higher than that of those without (95% CI: 1.19-5.92, p = 0.017) after adjusting for confounders in ETs. Similarly, the adjusted odds ratio (OR) was 2.43 (95% CI: 1.10-5.40, p = 0.029) in FETs. For the meta-analysis, eight studies met the inclusion criteria; however, only six reported the adjusted ORs. Combination of these six adjusted ORs with our results revealed that the GnRHa pre-treatment group had higher LBRs than the non-GnRHa pre-treatment group (ET: OR 1.71, 95% CI: 1.30-2.26, FET: OR 2.61, 95% CI: 1.52-4.49). CONCLUSIONS: In women with adenomyosis, GnRHa pre-treatment may be beneficial for LBRs following both ETs and FETs.
引用
- Li X, Li Y, Peng H, et al. Effect of Gonadotropin-Releasing Hormone Agonist Pre-Treatment on Outcomes of Fresh and Frozen Embryo Transfers in Women With Adenomyosis: A Retrospective Cohort Study With Literature Review. BJOG. 2024. PMID: 39688600. doi:10.1111/1471-0528.18026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。